EMA: New product-specific guidances [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2022-04-08 15:17 (38 d 06:11 ago) – Posting: # 22918
Views: 1,146

Dear all,

on April 04 the EMA published revised draft product-specific guidances for ibuprofen, paracetamol, and tadalafil. In the footnote on page 1 we find:

* This revision concerns defining what is meant by ‘comparable’ Tmax as an additional main pharmacokinetic vari­able in the bioequivalence assessment section of the guideline.

Then:

Bioequivalence assessment: Comparable median (≤ 20% difference) and range for Tmax.


See there why I consider this invention crap.
In short: tmax follows a discrete distribution on an [image] interval scale. Calculating the ratio of values is a questionable procedure.

End of consultation 31 July 2022.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,074 posts in 4,629 threads, 1,565 registered users;
online 13 (0 registered, 13 guests [including 9 identified bots]).
Forum time: Monday 21:29 CEST (Europe/Vienna)

Rules are for the guidance of wise men
and the blind obedience of fools.    attributed to Solon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5